• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个乳腺癌网络实现了与监测、流行病学和最终结果(SEER)数据库的融合:5年相对生存率的纵向基准。

Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival.

作者信息

Jacke Christian O, Albert Ute S, Reinhard Iris, Kalder Matthias

机构信息

Central Institute of Mental Health, Medical Faculty Mannheim, University Heidelberg, Square J5, 68159, Mannheim, Germany,

出版信息

J Cancer Res Clin Oncol. 2015 Jun;141(6):1109-18. doi: 10.1007/s00432-014-1879-9. Epub 2014 Dec 16.

DOI:10.1007/s00432-014-1879-9
PMID:25512079
Abstract

PURPOSE

To benchmark outcomes of a German breast cancer network with the Surveillance Epidemiology and End Results programme (SEER) of the USA from a longitudinal point of view.

METHODS

All women receiving primary breast cancer therapy of three hospitals in a rural district of Marburg-Biedenkopf (Germany) of time intervals 1996-1997 and 2003-2004 were used to define local benchmark objects. Data from SEER-programme contributed longitudinal benchmark objects from national level (1988-2004). All benchmark objects were compared with the time-fixed benchmark reference of SEER (2004). Stage distributions and 5-year relative survival ratios were combined to estimate standardized screening-, case-mix-, work-up-, treatment- and relative overall performance index.

RESULTS

From the entry cohort of 877 German women, 97.7 % of the patients accounted for the institutional sample (N = 857) and 65.8 % accounted for the regional sample (N = 577). Stage distributions, relative survival ratios and indices of the German breast cancer network improved over time. Developed indices converged with SEER (2004).

CONCLUSIONS

Effectiveness gap between one exemplary German breast cancer network and international benchmark defined by SEER has been closed. Reasons are manifold, and further research is recommended.

摘要

目的

从纵向角度将德国乳腺癌网络的结果与美国监测、流行病学和最终结果计划(SEER)进行对比。

方法

1996 - 1997年以及2003 - 2004年期间,德国马尔堡 - 比登科普夫农村地区三家医院接受原发性乳腺癌治疗的所有女性被用于定义当地的基准对象。SEER计划的数据提供了国家层面(1988 - 2004年)的纵向基准对象。所有基准对象均与SEER的固定时间基准参考(2004年)进行比较。结合阶段分布和5年相对生存率来估计标准化筛查、病例组合、检查、治疗和相对总体表现指数。

结果

在877名德国女性的入组队列中,97.7%的患者构成机构样本(N = 857),65.8%的患者构成区域样本(N = 577)。德国乳腺癌网络的阶段分布、相对生存率和指数随时间有所改善。所制定的指数与SEER(2004年)的数据趋于一致。

结论

德国一个示例性乳腺癌网络与SEER定义的国际基准之间的有效性差距已消除。原因是多方面的,建议进一步开展研究。

相似文献

1
Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival.一个乳腺癌网络实现了与监测、流行病学和最终结果(SEER)数据库的融合:5年相对生存率的纵向基准。
J Cancer Res Clin Oncol. 2015 Jun;141(6):1109-18. doi: 10.1007/s00432-014-1879-9. Epub 2014 Dec 16.
2
The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.不同原发性乳腺癌治疗后监测性乳房 X 光造影方案的临床效果和成本效益:系统评价注册库分析和经济评估。
Health Technol Assess. 2011 Sep;15(34):v-vi, 1-322. doi: 10.3310/hta15340.
3
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
6
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.用于预防或治疗早期乳腺癌中芳香化酶抑制剂引起的肌肉骨骼症状的系统治疗。
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD013167. doi: 10.1002/14651858.CD013167.pub2.
7
Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer.社会决定因素和肿瘤生物学与早期激素依赖性乳腺癌生存的种族差异相关。
JAMA Oncol. 2023 Apr 1;9(4):536-545. doi: 10.1001/jamaoncol.2022.7705.
8
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.乳腺密度、内分泌治疗与乳腺癌风险:预后和预测生物标志物综述。
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
9
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.对携带BRCA1或BRCA2基因突变的女性进行降低风险的双侧输卵管卵巢切除术。
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2.
10
Hormonal therapies for early breast cancer: systematic review and economic evaluation.早期乳腺癌的激素疗法:系统评价与经济学评估
Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. doi: 10.3310/hta11260.

引用本文的文献

1
Quantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis.量化治疗延迟对乳腺癌生存结果的影响:一项全面的荟萃分析。
Geroscience. 2025 Jun 10. doi: 10.1007/s11357-025-01719-1.
2
The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients.依从性悖论:指南偏差有助于提高乳腺癌患者的5年生存率。
BMC Cancer. 2015 Oct 19;15:734. doi: 10.1186/s12885-015-1765-0.

本文引用的文献

1
Epidemiology of Breast Cancer - Current Figures and Trends.乳腺癌流行病学——当前数据与趋势
Geburtshilfe Frauenheilkd. 2013 Feb;73(2):130-135. doi: 10.1055/s-0032-1328075.
2
Using relative survival measures for cross-sectional and longitudinal benchmarks of countries, states, and districts: the BenchRelSurv- and BenchRelSurvPlot-macros.使用相对生存测量来评估国家、州和地区的横断和纵向基准:BenchRelSurv- 和 BenchRelSurvPlot-宏。
BMC Public Health. 2013 Jan 14;13:34. doi: 10.1186/1471-2458-13-34.
3
Valid comparisons and decisions based on clinical registers and population based cohort studies: assessing the accuracy, completeness and epidemiological relevance of a breast cancer query database.
基于临床登记和人群队列研究的有效比较与决策:评估乳腺癌查询数据库的准确性、完整性和流行病学相关性。
BMC Res Notes. 2012 Dec 27;5:700. doi: 10.1186/1756-0500-5-700.
4
[Systematic assessment and improvement of medical data quality].[医学数据质量的系统评估与改进]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Nov;55(11-12):1495-503. doi: 10.1007/s00103-012-1536-x.
5
Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany.德国和美国基于人群的乳腺癌生存趋势:差异逐渐缩小,但德国老年患者的生存差距仍然存在。
BMC Cancer. 2012 Jul 28;12:317. doi: 10.1186/1471-2407-12-317.
6
Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit.初诊于认证学术乳腺专科的原发性乳腺癌患者的疗效分析。
Breast. 2012 Jun;21(3):303-8. doi: 10.1016/j.breast.2012.01.009. Epub 2012 Feb 5.
7
The decline in breast cancer mortality in Europe: an update (to 2009).欧洲乳腺癌死亡率的下降:最新情况(截至 2009 年)。
Breast. 2012 Feb;21(1):77-82. doi: 10.1016/j.breast.2011.08.001. Epub 2011 Sep 8.
8
Survival from common and rare cancers in Germany in the early 21st century.21 世纪初德国常见和罕见癌症的生存情况。
Ann Oncol. 2012 Feb;23(2):472-9. doi: 10.1093/annonc/mdr131. Epub 2011 May 19.
9
Optimizing the quality of breast cancer care at certified german breast centers: a benchmarking analysis for 2003-2009 with a particular focus on the interdisciplinary specialty of radiation oncology.优化德国认证乳腺癌中心的乳腺癌护理质量:2003-2009 年的基准分析,特别关注放射肿瘤学的跨学科专业。
Strahlenther Onkol. 2011 Feb;187(2):89-99. doi: 10.1007/s00066-010-2202-6. Epub 2011 Jan 21.
10
Caution needed for country-specific cancer survival.特定国家的癌症生存率需谨慎对待。
Lancet. 2011 Jan 8;377(9760):99-101. doi: 10.1016/S0140-6736(10)62347-1.